Literature DB >> 16670827

Use of antibodies recognizing cyclic citrullinated peptide in the differential diagnosis of joint involvement in systemic sclerosis.

Francesca Ingegnoli1, Valentina Galbiati, Silvana Zeni, Laura Meani, Lenka Zahalkova, Chiara Lubatti, Amedeo Soldi, Erberto Paresce, Antonella Murgo, Calogero Crapanzano, Flavio Fantini.   

Abstract

OBJECTIVE: To determine the prevalence of anti-cyclic citrullinated peptide (CCP) antibodies in systemic sclerosis (SSc) and to assess any association between the presence of anti-CCP, radiographic features, and clinical manifestations.
MATERIALS AND METHODS: Anti-CCP antibodies and rheumatoid factor (RF) were tested in serum samples from 75 patients with SSc (64 women and 11 men), with a mean age of 59.4 years (range 24-85) with either diffuse (dcSSc) and limited (lcSSc) cutaneous involvement. As a control group, 22 age- and sex-matched healthy controls (HCs) were examined. Standard radiographs of the hands and wrists were examined in each patient.
RESULTS: The presence of anti-CCP was found in sera of 10.6% (8/75) patients with SSc (lcSSc 3 of 44, 6.8%; dcSSc 5 of 31, 16.1%). None of the HCs was positive for anti-CCP. The positivity of RF was observed in 19 of 75 (25.3%) SSc patients (lcSSc 10 of 44, 22.7%; dcSSc 9 of 31, 29%). Statistically significant association was found between anti-CCP positivity and the presence of arthritis (p<0.0001) and marginal erosions (p=0.001).
CONCLUSION: Our data show that joint involvement is a common presenting feature of SSc. In this report, we show that anti-CCP antibodies can be detected also in patients with SSc, but they are generally less commonly present than in adults with rheumatoid arthritis (RA). Thus, the finding of high titers of anti-CCP antibodies may help to define the diagnosis of overlap syndrome SSc/RA and facilitate diagnosis and appropriate treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16670827     DOI: 10.1007/s10067-006-0313-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  14 in total

Review 1.  Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients.

Authors:  Clodoveo Ferri; Gabriele Valentini; Franco Cozzi; Marco Sebastiani; Claudio Michelassi; Giovanni La Montagna; Arianna Bullo; Massimiliano Cazzato; Enrico Tirri; Franca Storino; Dilia Giuggioli; Giovanna Cuomo; Mara Rosada; Stefano Bombardieri; Silvano Todesco; Giuseppe Tirri
Journal:  Medicine (Baltimore)       Date:  2002-03       Impact factor: 1.889

2.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

Authors:  E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

3.  The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.

Authors:  G A Schellekens; H Visser; B A de Jong; F H van den Hoogen; J M Hazes; F C Breedveld; W J van Venrooij
Journal:  Arthritis Rheum       Date:  2000-01

4.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

5.  The arthropathy of systemic sclerosis: a 12 month prospective clinical and imaging study.

Authors:  Giovanni La Montagna; Antonio Sodano; Vittorio Capurro; Domenico Malesci; Gabriele Valentini
Journal:  Skeletal Radiol       Date:  2004-09-17       Impact factor: 2.199

6.  Coexistence of rheumatoid arthritis and systemic sclerosis in four patients.

Authors:  M J Cohen; R H Persellin
Journal:  Scand J Rheumatol       Date:  1982       Impact factor: 3.641

Review 7.  The coexistence of systemic sclerosis and rheumatoid arthritis in five patients. Clinical and immunogenetic features suggest a distinct entity.

Authors:  T Horiki; J Moriuchi; M Takaya; M Uchiyama; Y Hoshina; K Inada; H Inoko; K Tsuji; Y Ichikawa
Journal:  Arthritis Rheum       Date:  1996-01

8.  Arthritis in scleroderma.

Authors:  R Misra; K Darton; R F Jewkes; C M Black; R N Maini
Journal:  Br J Rheumatol       Date:  1995-09

9.  Scleroderma and erosive polyarthritis: a disease entity?

Authors:  R D Armstrong; T Gibson
Journal:  Ann Rheum Dis       Date:  1982-04       Impact factor: 19.103

10.  The concurrence of rheumatoid arthritis and limited systemic sclerosis: clinical and serologic characteristics of an overlap syndrome.

Authors:  C Zimmermann; G Steiner; K Skriner; W Hassfeld; P Petera; J S Smolen
Journal:  Arthritis Rheum       Date:  1998-11
View more
  16 in total

Review 1.  Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis.

Authors:  Rohit Aggarwal; Katherine Liao; Raj Nair; Sarah Ringold; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2009-11-15

Review 2.  Antibodies to citrullinated protein antigens (ACPAs): clinical and pathophysiologic significance.

Authors:  M Kristen Demoruelle; Kevin Deane
Journal:  Curr Rheumatol Rep       Date:  2011-10       Impact factor: 4.592

3.  Anti-cyclic citrullinated peptide antibodies in scleroderma patients.

Authors:  M Polimeni; D Feniman; T S Skare; Renato M Nisihara
Journal:  Clin Rheumatol       Date:  2012-01-04       Impact factor: 2.980

4.  The frequency of antibodies against cyclic citrullinated peptides and rheumatoid factor in healthy population: a field study of rheumatoid arthritis from northern Turkey.

Authors:  Turker Tasliyurt; Bunyamin Kisacik; Suheyla Uzun Kaya; Beytullah Yildirim; Yavuz Pehlivan; Faruk Kutluturk; Huseyin Ozyurt; Semsettin Sahin; Ahmet Mesut Onat
Journal:  Rheumatol Int       Date:  2012-07-25       Impact factor: 2.631

5.  Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease samples: citrulline-dependent or not?

Authors:  A Vannini; K Cheung; M Fusconi; J Stammen-Vogelzangs; J P H Drenth; A C Dall'Aglio; F B Bianchi; L E Bakker-Jonges; W J van Venrooij; G J M Pruijn; A J W Zendman
Journal:  Ann Rheum Dis       Date:  2006-09-19       Impact factor: 19.103

6.  Evaluating hand in systemic sclerosis.

Authors:  Didem Arslan Tas; Eren Erken; Hakan Sakalli; A Eftal Yucel
Journal:  Rheumatol Int       Date:  2011-11-17       Impact factor: 2.631

7.  A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis.

Authors:  Mittermayer Santiago; Murray Baron; Kiyomitsu Miyachi; Marvin J Fritzler; M Abu-Hakima; S Leclercq; M Bell; M Hudson; J-P Mathieu; S Taillefer; N Jones; P Docherty; M Khraishi; J Markland; J Pope; D Robinson; D Smith; E Sutton
Journal:  Clin Rheumatol       Date:  2007-06-15       Impact factor: 2.980

Review 8.  The role of anti-cyclic cytrullinate antibodies testing in rheumatoid arthritis.

Authors:  Cristiano Alessandri; Roberta Priori; Mariagrazia Modesti; Riccardo Mancini; Guido Valesini
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

9.  Prevalence of autoantibodies to cyclic citrullinated peptide in patients with rheumatic diseases other than rheumatoid arthritis: a French multicenter study.

Authors:  Nicole Fabien; Nils-Olivier Olsson; Joëlle Goetz; Catherine Johanet; Andrée Escande; Nathalie Bardin; Marielle Sanmarco; Chantal Andre; Alain Chevailler; René-Louis Humbel; Pascale Chretien; Jean-claude Monier; Françoise Fortenfant; Françoise Oksman; Marie-France Taillefer; Jean Sibilia
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

10.  Raynaud's phenomenon, inflammatory arthritis, and weight loss: pay attention to the man behind the curtain.

Authors:  George Stojan; Peter B Illei; Rex C Yung; Allan C Gelber
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-08       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.